How to treat patients with chronic kidney disease: With special focus on IgA nephropathy.

Chronic kidney disease has become a worldwide problem. Among chronic kidney disease patients, IgA nephropathy is common in the world. Serum levels of galactose deficient (Gd)‐IgA1 and Gd‐IgA1‐specific antibodies are elevated in most IgA nephropathy patients. Glomerular Gd‐IgA1 deposition has been observed by immunofluorescence. There are many reports that the anti‐proteinuric effect is significantly greater in groups who receive tonsillectomy with steroid pulse therapy in IgA nephropathy patients. Furthermore, patients with tonsillectomy with steroid pulse therapy have shown a strong down‐regulation of delta serum IgA/C3 per year and have conserved their renal function. New treatments, that is, Atacicept and glucocorticoid budesonide, have been developed for this disease. Summary at a Glance: IgA nephropathy is a major cause of CKD in the world. Using of new biomarkers, we should select the treatment for the patients with IgA nephropathy. [ABSTRACT FROM AUTHOR]